NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free CERS Stock Alerts $1.86 +0.01 (+0.54%) (As of 03:27 PM ET) Add Compare Share Share Today's Range$1.75▼$1.8850-Day Range$1.62▼$2.4252-Week Range$1.21▼$3.08Volume972,067 shsAverage Volume1.47 million shsMarket Capitalization$343.88 millionP/E RatioN/ADividend YieldN/APrice Target$3.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cerus alerts: Email Address Cerus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside106.1% Upside$3.83 Price TargetShort InterestHealthy3.20% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 14 Articles This WeekInsider TradingSelling Shares$372,912 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.09) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector450th out of 905 stocksSurgical & Medical Instruments Industry57th out of 95 stocks 3.3 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCerus has only been the subject of 3 research reports in the past 90 days.Read more about Cerus' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.20% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cerus has recently increased by 0.68%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 2.2 News and Social Media Coverage News SentimentCerus has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Cerus this week, compared to 2 articles on an average week.Search Interest8 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $372,912.00 in company stock.Percentage Held by InsidersOnly 7.05% of the stock of Cerus is held by insiders.Percentage Held by Institutions78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.09) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -10.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -10.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 6.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityRSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.Register For Free Now! About Cerus Stock (NASDAQ:CERS)Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.Read More CERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERS Stock News HeadlinesMay 6, 2024 | americanbankingnews.comCerus (NASDAQ:CERS) Price Target Raised to $4.00May 5, 2024 | markets.businessinsider.comCerus’s Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy RatingMay 8, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 4, 2024 | finance.yahoo.comCerus First Quarter 2024 Earnings: EPS Misses ExpectationsMay 3, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Joint (JYNT) and Cerus (CERS)May 3, 2024 | finance.yahoo.comCerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 3, 2024 | finance.yahoo.comQ1 2024 Cerus Corp Earnings CallMay 3, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.May 2, 2024 | investorplace.comCERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024May 2, 2024 | sfgate.comCerus: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comCerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss NarrowsMay 2, 2024 | businesswire.comCerus Corporation Announces First Quarter 2024 Financial ResultsApril 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cerus (CERS), MiMedx Group (MDXG)April 18, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%April 18, 2024 | businesswire.comCerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024April 12, 2024 | markets.businessinsider.comCerus Corporation: Strong Buy Rating Amidst Growth and Path to ProfitabilityApril 12, 2024 | msn.comCerus gains as Craig Hallum launches at Buy on return to growthMarch 28, 2024 | stockhouse.comCerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf LifeMarch 26, 2024 | markets.businessinsider.comCerus: FDA Approves 12-month Shelf Life For INTERCEPT Platelet Processing SetsMarch 26, 2024 | finance.yahoo.comCerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf LifeMarch 19, 2024 | msn.comWhy Blood Components-Focused Cerus Stock Is Rising TuesdayMarch 19, 2024 | markets.businessinsider.comCerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ RatingMarch 19, 2024 | markets.businessinsider.comCerus Announces Positive Results For Phase 3 Trial Of Intercept Blood SystemMarch 19, 2024 | msn.comCerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patientsMarch 19, 2024 | finance.yahoo.comCerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery PatientsMarch 16, 2024 | ca.finance.yahoo.comCERS Apr 2024 3.000 callSee More Headlines Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/08/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees625Year Founded1991Price Target and Rating Average Stock Price Target$3.83 High Stock Price Target$5.00 Low Stock Price Target$2.50 Potential Upside/Downside+111.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,490,000.00 Net Margins-19.27% Pretax Margin-19.16% Return on Equity-58.65% Return on Assets-15.14% Debt Debt-to-Equity Ratio1.29 Current Ratio2.41 Quick Ratio1.72 Sales & Book Value Annual Sales$156.37 million Price / Sales2.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book6.24Miscellaneous Outstanding Shares184,890,000Free Float171,855,000Market Cap$334.65 million OptionableOptionable Beta1.31 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. William M. Greenman (Age 57)President, CEO & Director Comp: $1.04MMr. Kevin D. Green (Age 52)VP of Finance & CFO Comp: $607.53kMr. Vivek K. Jayaraman (Age 49)Chief Operating Officer Comp: $696.68kMs. Chrystal Jensen (Age 53)Chief Legal Officer & General Counsel Comp: $571.49kDr. Richard J. Benjamin MBChB (Age 64)Ph.D., Chief Medical Officer Comp: $603.68kDr. Laurence M. Corash (Age 80)Co-Founder & Chief Scientific Officer Comp: $697.77kMs. Lori L. RollVP of Administration & Corporate SecretaryMr. Matthew M. NotarianniSenior Director of Investor RelationsLainie CortenVice President of Global MarketingMs. Alicia GoodmanChief Human Resources OfficerMore ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDAtrionNASDAQ:ATRITactile Systems TechnologyNASDAQ:TCMDView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Bought 12,179 shares on 5/8/2024Ownership: 0.008%Nikko Asset Management Americas Inc.Bought 182,629 shares on 5/3/2024Ownership: 4.192%GSA Capital Partners LLPSold 147,339 shares on 5/3/2024Ownership: 0.463%Easterly Investment Partners LLCBought 214,286 shares on 5/3/2024Ownership: 0.116%BNP Paribas Financial MarketsBought 121,364 shares on 5/1/2024Ownership: 0.118%View All Insider TransactionsView All Institutional Transactions CERS Stock Analysis - Frequently Asked Questions Should I buy or sell Cerus stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CERS shares. View CERS analyst ratings or view top-rated stocks. What is Cerus' stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Cerus' stock. Their CERS share price targets range from $2.50 to $5.00. On average, they predict the company's share price to reach $3.83 in the next year. This suggests a possible upside of 106.1% from the stock's current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. How have CERS shares performed in 2024? Cerus' stock was trading at $2.16 at the start of the year. Since then, CERS stock has decreased by 13.9% and is now trading at $1.8599. View the best growth stocks for 2024 here. Are investors shorting Cerus? Cerus saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,880,000 shares, an increase of 16.0% from the March 15th total of 5,070,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is currently 3.6 days. View Cerus' Short Interest. When is Cerus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our CERS earnings forecast. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) released its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). The biotechnology company had revenue of $46.77 million for the quarter, compared to the consensus estimate of $46.80 million. Cerus had a negative trailing twelve-month return on equity of 58.65% and a negative net margin of 19.27%. What ETFs hold Cerus' stock? ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK). What guidance has Cerus issued on next quarter's earnings? Cerus updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $172.0 million-$175.0 million, compared to the consensus revenue estimate of $190.9 million. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA). Who are Cerus' major shareholders? Cerus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (4.19%), Sumitomo Mitsui Trust Holdings Inc. (4.28%), Wasatch Advisors LP (3.47%), Assenagon Asset Management S.A. (0.61%), GSA Capital Partners LLP (0.46%) and Bouvel Investment Partners LLC (0.15%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Jensen, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Vivek K Jayaraman and William Mariner Greenman. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
